Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study

José, Ana Pérez de; Carbayo, Javier; Pocurull, Anna; Bada-Bosch, Teresa; Corona, Clara María Cases; Shabaka, Amir; Terrada, Natàlia Ramos; Valenzuela, Laura Martínez; Huerta, Ana; Lorente, Loreto Fernández; Malek-Marín, Tamara Gelen; Goicoechea, Marián

doi:10.1093/ckj/sfz178

Cited by 12 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While Sise et al (22) found no change in kidney function during treatment course as patients experienced minor fluctuations in serum creatinine and did not change >0.3 mg/dL from baseline at any time during treatment. Other studies agree with our results and describe improvement in eGFR after viral clearance (18,20,23) .…”

Section: Discussionsupporting

confidence: 93%

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Similar results were detected by Reddy et al, [14] who documented that there is statistical significant difference regarding creatinine as treated patients with HCC group creatinine was lower than untreated patients with HCC group (P < 001). Also Ana et al, [15] documented that DAA treatment in patients with HCV improves kidney survival and reduces creatinine.…”

Section: Discussionmentioning

confidence: 99%

Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis After Treatment with Direct Acting Antiviral Therapy

Elkady

El-Toukhy

El-Wahhab

2021

Benha Journal of Applied Sciences

View full text Add to dashboard Cite

Aim: this study aimed to clarify the possible effect of direct acting antivirals (DAAs) treatment on development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) cirrhotic patients. , Methods: this study was conducted on 400 chronic hepatitis C cirrhotic patients, divided into two groups according to treatment with DAAs, group I including (200 Patients with chronic HCV cirrhosis treated with DAAs), and group II including (200 patients with chronic HCV cirrhosis without DAAs treatment), all patients were recruited from the Gastroenterology and Hepatology department Kobry Elkobba Military Hospital, all patients were males with no previous history of HCC, human immunodeficiency virus (HIV) or hepatitis B virus (HBV) infection or history of liver transplantation. After one year of follow up all patients were divided into further two subgroups according HCC development, group III ( 11 HCV cirrhotic patients treated with DAAs (sofosbuvir and daclatasvir) and developed HCC) and group IV (22 HCV cirrhotic patients not treated and developed HCC).Results: HCC developed more in not treated group with a significant difference as 11% of not treated group developed HCC compared to 5.5% only of treated group (P=0.046). using univariate cox regression, it was shown that no treatment was an independent risk factor of getting hepatocellular carcinoma (HCC), as cases not receiving the study treatment are at higher risk for developing HCC (HR=3.4, P=0.002). conclusion: DAA treatment is not associated with a higher risk of HCC in cirrhotic patients with chronic HCV infection in the short-term. The occurrence of HCC is significantly decreased in patients treated with DAAs.

show abstract

“…In these secondary cases, treatment of the underlying condition—immunosuppression for autoimmune diseases, antiviral drugs and antibiotics for viral and bacterial infections—often also improves kidney injury and dysfunction (Fig. 2 ) [ 2 , 10 , 11 ].…”

Section: Treatment Standardsmentioning

confidence: 99%

C3G and Ig-MPGN—treatment standard

Noris,

Remuzzi

2023

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Among the broad spectrum of membranoproliferative glomerulonephritis (MPGN), immunofluorescence distinguishes C3 glomerulopathy (C3G), with predominant C3 deposits, and immunoglobulin-associated MPGN (Ig-MPGN), with combined C3 and Ig. However, there are several intersections between C3G and Ig-MPGN. Primary C3G and Ig-MPGN share the same prevalence of low serum C3 levels and of abnormalities of the alternative pathway of complement, and patients who present a bioptic pattern of Ig-MPGN at onset may show a C3G pattern in a subsequent biopsy. There is no specific therapy for primary C3G and Ig-MPGN and prognosis is unfavourable. The only recommended indications are inhibitors of the renin–angiotensin system, lipid-lowering agents and other renoprotective agents. The other drugs used currently, such as corticosteroids and mycophenolate mofetil, are often ineffective. The anti-C5 monoclonal antibody eculizumab has been tested in several patients, with mixed results. One reason for the uncertainty is the extremely variable clinical course, most likely reflecting a heterogeneous pathogenesis. An unsupervised clustering analysis that included histologic, biochemical, genetic and clinical data available at onset in patients with primary C3G and Ig-MPGN identified four clusters characterized by specific pathogenic mechanisms. This approach may facilitate accurate diagnosis and development of targeted therapies. Several trials are ongoing with drugs targeting different molecules of the complement cascade, however it is important to consider which component of the cascade may be the most appropriate for each patient. We review the current standards of treatment and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of C3G and Ig-MPGN.

show abstract

Direct-acting antiviral therapy improves kidney survival in hepatitis C virus-associated cryoglobulinaemia: the RENALCRYOGLOBULINEMIC study

Cited by 12 publications

References 21 publications

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease

Impact of direct acting antiviral agents on kidney function in hepatitis C virus infected patients with chronic kidney disease

Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis After Treatment with Direct Acting Antiviral Therapy

C3G and Ig-MPGN—treatment standard

Contact Info

Product

Resources

About